Biopharma Should Copy Our Gilead Deal, Says Rising Star Galapagos
‘Standstill’ Guarantees Biotech’s Independence
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.